Poorly differentiated thyroid carcinoma: a clinician's perspective
J Tong, M Ruan, Y Jin, H Fu, L Cheng… - European Thyroid …, 2022 - etj.bioscientifica.com
Poorly differentiated thyroid carcinoma (PDTC) is a rare thyroid carcinoma originating from
follicular epithelial cells. No explicit consensus can be achieved to date due to sparse …
follicular epithelial cells. No explicit consensus can be achieved to date due to sparse …
ANXA1 (Annexin A1) regulated by MYC (MYC proto-oncogene) promotes the growth of papillary thyroid carcinoma
X Ying, L Chen, J Xie, Y Hu, Q Wu, L Cao, H Yu - Bioengineered, 2021 - Taylor & Francis
Thyroid carcinoma is one of the most common endocrine malignancies, in which papillary
thyroid carcinoma (PTC) is the main pathotype. ANXA1 plays a significant role in many …
thyroid carcinoma (PTC) is the main pathotype. ANXA1 plays a significant role in many …
[HTML][HTML] Relationship of PPARG overexpression with prognostic parameters in papillary thyroid carcinoma
O Asya, AC Yumuşakhuylu, P Bağcı… - Acta …, 2022 - ncbi.nlm.nih.gov
Objectives PAX8/PPARG chromosomal rearrangement is frequently seen in thyroid cancer,
and PPARG overexpression has been shown in the follicular variant of papillary thyroid …
and PPARG overexpression has been shown in the follicular variant of papillary thyroid …
The association between the interval of radioiodine treatment and treatment response, and side effects in patients with lung metastases from differentiated thyroid …
H Wang, L Shi, R Huang, B Liu, R Tian - Frontiers in Endocrinology, 2023 - frontiersin.org
Objective Repeat radioiodine (RAI) treatment has been widely implemented for RAI-avid
lung metastases and is clinically effective for lung metastatic differentiated thyroid cancer …
lung metastases and is clinically effective for lung metastatic differentiated thyroid cancer …
Optimizing the indication of initial radioiodine oncolytic treatment for metastatic differentiated thyroid cancer by diagnostic 131I scan
Z He, R Sa, K Zhang, J Wang, X Qiu, L Chen - Clinical Radiology, 2024 - Elsevier
AIM As a classic theranostic radiopharmaceutical, radioiodine (131 I) has been utilized in
the management of differentiated thyroid cancer (DTC) for more than 8 decades, and the …
the management of differentiated thyroid cancer (DTC) for more than 8 decades, and the …
Predictive value of thyroglobulin changes for the curative effect of radioiodine therapy in patients with metastatic differentiated thyroid carcinoma
C Wang, R Zhang, R Wang, Z Meng, G Zhang… - Frontiers in …, 2021 - frontiersin.org
Background Serum thyroglobulin (Tg) serves as a sensitive and easily available tumor
marker for patients with metastatic differentiated thyroid carcinoma (m-DTC). The aim of the …
marker for patients with metastatic differentiated thyroid carcinoma (m-DTC). The aim of the …
Do radioiodine-avid lymph nodes from differentiated thyroid cancer on the initial posttherapy scan need repeated 131I therapy?
Y Jiang, S Liu, X Qiu, Y Huo, X Zhang, H Cai… - Frontiers in …, 2023 - frontiersin.org
Background Residual/recurrent lymph node metastase (LNM) is often found after
differentiated thyroid cancer (DTC) surgery. This study aimed to investigate whether patients …
differentiated thyroid cancer (DTC) surgery. This study aimed to investigate whether patients …
The Association Between The Interval of Radioiodine Treatment and The Response and Adverse Effect in Patients with Non-Progressive Lung Metastases From …
H Wang, R Tian, L Shi, R Huang, B Liu - 2021 - researchsquare.com
Purpose To assess the association between the interval of radioiodine treatment (RT) and
short-term response and adverse effects in patients with non-progressive lung metastases …
short-term response and adverse effects in patients with non-progressive lung metastases …